CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis
Background and aims: Alemtuzumab is a humanized monoclonal antibody that depletes CD52-bearing B and T lymphocytes. Clinical trials defined that systemic administration of alemtuzumab reduces disease severity in the relapsing-remitting phase of multiple sclerosis (MS). However, its efficacy in progr...
Bewaard in:
| Hoofdauteurs: | , , , , , , |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
SAGE Publishing,
2020-08-01T00:00:00Z.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
| Plaatsingsnummer: |
A1234.567 |
|---|---|
| Kopie 1 | Beschikbaar |